Biomarkers of Alzheimer's disease in body fluids

Science China Life Sciences

Volumn 53, Issue 4, 2010, Pages 490-496

  Zheng, Yan Peng ^a   He, Jin Sheng ^a   Hong, Tao ^a,b  

^a BEIJING JIAOTONG UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Plasma

Indexed keywords

BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; BLOOD; BODY FLUID; CEREBROSPINAL FLUID; DEMENTIA; DISEASE COURSE; HUMAN; METABOLISM; NEUROFIBRILLARY TANGLE; REVIEW;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BODY FLUIDS; DEMENTIA; DISEASE PROGRESSION; HUMANS; NEUROFIBRILLARY TANGLES;

EID: 77952302670     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-010-0081-9     Document Type: Review

References (71)

1. Borroni B, Di Luca M, Padovani A. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful? Eur J Pharmacol, 2006, 545: 73-80.
2. Zetterberg H. Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease? Recent Pat CNS Drug Discov, 2008, 3: 109-111.
3. Clark C M, Davatzikos C, Borthakur A, et al. Biomarkers for early detection of Alzheimer pathology Neurosignals, 2008, 16: 11-18.
4. Tamaoka A, Odaka A, Ishibashi Y, et al. APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain. J Biol Chem, 1994, 269: 32721-32724.
5. van Nostrand W E, Wagner S L, Shankle W R, et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci USA, 1992, 89: 2551-2555.
6. Palmert M R, Usiak M, Mayeux R, et al. Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: Alterations in normal aging and in Alzheimer's disease. Neurology, 1990, 40: 1028-1034.
7. Simonsen A H, Hansson S F, Ruetschi U, et al. Amyloid beta 1-40 quantification in CSF: Comparison between chromatographic and immunochemical methods. Dement Geriatr Cogn Disord, 2007, 23: 246-250.
8. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol, 1995, 38: 643-648.
9. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer's disease: Differences between early- and late-onset Alzheimer's disease and stability during the course of disease. Arch Neurol, 1999, 56: 673-680.
10. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol, 2001, 58: 373-379.
11. Prince J A, Zetterberg H, Andreasen N, et al. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology, 2004, 62: 2116-2118.
12. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology, 1999, 52: 1555-1562.
13. Kapaki E, Kilidireas K, Paraskevas G P, et al. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: A discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry, 2001, 71: 401-403.
14. Otto M, Esselmann H, Schulz-Shaeffer W, et al. Decreased betaamyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology, 2000, 54: 1099-1102.
15. Tapiola T, Pirttila T, Mikkonen M, et al. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett, 2000, 280: 119-122.
16. Riemenschneider M, Schmolke M, Lautenschlager N, et al. Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett, 2000, 284: 85-88.
17. Vanderstichele H, van Kerschaver E, Hesse C, et al. Standardization of measurement of beta-amyloid (1-42) in cerebrospinal fluid and plasma. Amyloid, 2000, 7: 245-258.
18. Gustafson D R, Skoog I, Rosengren L, et al. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry, 2007, 78: 461-464.
19. Gloeckner S F, Meyne F, Wagner F, et al. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis, 2008, 14: 17-25.
20. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: A study in Japan. Ann Neurol, 1998, 44: 17-26.
21. Wiltfang J, Esselmann H, Bibl M, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem, 2007, 101: 1053-1059.
22. Ringman J M, Younkin S G, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology, 2008, 71: 85-92.
23. Kaiser E, Schonknecht P, Thomann P A, et al. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci Lett, 2007, 417: 193-195.
24. Gelfanova V, Higgs R E, Dean R A, et al. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief Funct Genomic Proteomic, 2007, 6: 149-158.
25. Verpillot R, Otto M, Klafki H, et al. Simultaneous analysis by capillary electrophoresis of five amyloid peptides as potential biomarkers of Alzheimer's disease. J Chromatogr A, 2008, 1214: 157-164.
26. Höglund K, Hansson O, Buchhave P, et al. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. Neurodegener Dis, 2008, 5: 268-276.
27. Lue L F, Kuo Y M, Roher A E, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol, 1999, 155: 853-862.
28. McLean C A, Cherny R A, Fraser F W, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol, 1999, 46: 860-866.
29. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem, 1993, 61: 1828-1834.
30. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol, 2006, 5: 228-234.
31. Andreasen N, Sjogren M, Blennow K. CSF markers for Alzheimer's disease: Total tau, phospho-tau and Abeta42. World J Biol Psychiatry, 2003, 4: 147-155.
32. Buerger K, Teipel S J, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology, 2002, 59: 627-629.
33. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry, 2004, 61: 95-102.
34. Hampel H, Teipel S J, Fuchsberger T, et al. Value of CSF beta-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry, 2004, 9: 705-710.
35. Boban M, Grbic K, Mladinov M, et al. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia. Coll Antropol, 2008, 32(Suppl) 1: 31-36.
36. Stomrud E, Hansson O, Blennow K, et al. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord, 2007, 24: 118-124.
37. Engelborghs S, De Vreese K, van de Casteele T, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging, 2008, 29: 1143-1159.
38. Smach M A, Charfeddine B, Lammouchi T, et al. Interest of CSF beta-amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer's disease. Ann Biol Clin (Paris), 2008, 66: 531-535.
39. Bouwman F H, Schoonenboom N S, Verwey N A, et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging, 2009, 30: 1895-1901.
40. Sluimer J D, Bouwman F H, Vrenken H, et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiol Aging, 2008, (Epub ahead of print).
41. Fagan A M, Roe C M, Xiong C, et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol, 2007, 64: 343-349.
42. Kapaki E N, Paraskevas G P, Tzerakis N G, et al. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur J Neurol, 2007, 14: 168-173.
43. Schoonenboom N S, van der Flier W M, Blankenstein M A, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging, 2008, 29: 669-675.
44. Blennow K, Zetterberg H, Minthon L, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett, 2007, 419: 18-22.
45. Mehta P D, Pirttila T, Mehta S P, et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol, 2000, 57: 100-105.
46. Ertekin-Taner N, Younkin L H, Yager D M, et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology, 2008, 70: 596-606.
47. Tamaoka A, Fukushima T, Sawamura N, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci, 1996, 141: 65-68.
48. Fukumoto H, Tennis M, Locascio J J, et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol, 2003, 60: 958-964.
49. Lopez O L, Kuller L H, Mehta P D, et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology, 2008, 70: 1664-1671.
50. Mayeux R, Tang M X, Jacobs D M, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol, 1999, 46: 412-416.
51. Mayeux R, Honig L S, Tang M X, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: Relation to age, mortality, and risk. Neurology, 2003, 61: 1185-1190.
52. Locascio J J, Fukumoto H, Yap L, et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol, 2008, 65: 776-785.
53. Baranowska-Bik A, Bik W, Wolinska-Witort E, et al. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuro Endocrinol Lett, 2008, 29: 75-79.
54. Sundelof J, Giedraitis V, Irizarry M C, et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: A prospective, population-based cohort study. Arch Neurol, 2008, 65: 256-263.
55. Schupf N, Tang M X, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA, 2008, 105: 14052-14057.
56. Roher A E, Esh C L, Kokjohn T A, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement, 2009, 5: 18-29.
57. Lanz T A, Schachter J B. Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies. J Neurosci Methods, 2008, 169: 16-22.
58. Santos A N, Simm A, Holthoff V, et al. A method for the detection of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in blood using magnetic beads in combination with Flow cytometry and its application in the diagnostics of Alzheimer's disease. J Alzheimers Dis, 2008, 14: 127-131.
59. Gustaw K A, Garrett M R, Lee H G, et al. Antigen-antibody dissociation in Alzheimer disease: A novel approach to diagnosis. J Neurochem, 2008, 106: 1350-1356.
60. Giedraitis V, Sundelof J, Irizarry M C, et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett, 2007, 427: 127-131.
61. Matsushima H, Shimohama S, Fujimoto S, et al. Changes in platelet phospholipase C protein level and activity in Alzheimer's disease. Neurobiol Aging, 1995, 16: 895-900.
62. Ferrarese C, Begni B, Canevari C, et al. Glutamate uptake is decreased in platelets from Alzheimer's disease patients. Ann Neurol, 2000, 47: 641-643.
63. Zoia C, Cogliati T, Tagliabue E, et al. Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer's disease. Neurobiol Aging, 2004, 25: 149-157.
64. Padovani A, Borroni B, Colciaghi F, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol, 2002, 59: 71-75.
65. Borroni B, Colciaghi F, Corsini P, et al. Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms. Neurol Sci, 2002, 23: 207-210.
66. Borroni B, Colciaghi F, Caltagirone C, et al. Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: A 2-year follow-up study. Arch Neurol, 2003, 60: 1740-1744.
67. Liu Y, Wei H, Wang J, et al. Effects of randomizing the Sup35NM prion domain sequence on formation of amyloid fibrils in vitro. Biochem Biophys Res Commun, 2007, 353: 139-146.
68. Zhang Y, Qin K, Wang J, et al. Dividing roles of prion protein in staurosporine-mediated apoptosis. Biochem Biophys Res Commun, 2006, 349: 759-768.
69. Gao J M, Gao C, Han J, et al. Dynamic analyses of PrP and PrP(Sc) in brain tissues of golden hamsters infected with scrapie strain 263K revealed various PrP forms. Biomed Environ Sci, 2004, 17: 8-20.
70. Zhang F P, Zhang J, Zhou W, et al. Expression of PrP(C) as HISfusion form in a baculovirus system and conversion of expressed PrPsen to PrP-res in a cell-free system. Virus Res, 2002, 87: 145-153.
71. Lauren J, Gimbel D A, Nygaard H B, et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature, 2009, 457: 1128-1132.